News

VitalStream Offers Continuous Hemodynamic Monitoring Solution Amid IV Fluid Shortage

Caretaker Medical, a pioneer in advanced hemodynamic monitoring technology, is highlighting the critical role of its VitalStream solution in addressing the ongoing IV fluid shortage caused by Hurricane Helene. As healthcare providers face challenges in maintaining continuous blood pressure monitoring due to the limited availability of Baxter IV fluids, VitalStream offers a reliable and innovative alternative.

VitalStream provides continuous hemodynamic monitoring without the need for invasive arterial lines or continuous IV fluid infusion. This groundbreaking technology eliminates the reliance on IV fluids for blood pressure measurement, offering significant advantages during times of supply shortages. By providing real-time insights into a patient’s response to fluids, VitalStream can potentially reduce the overall need for IV fluid administration.

“The IV fluid shortage has created a significant challenge for healthcare providers across the country,” said Johnny Mann, VP Sales and Marketing at Caretaker Medical. “VitalStream offers a valuable solution by enabling continuous hemodynamic monitoring without the need for invasive lines or constant IV fluid infusion. This technology can help ensure patient safety and optimize fluid management during these challenging times.”

Caretaker Medical will be showcasing VitalStream at the upcoming American Society of Anesthesiologists (ASA) Conference in Philadelphia from October 19-21. Attendees will have the opportunity to learn more about this innovative technology and its potential benefits in addressing the current IV fluid shortage.

Learn more here.

Recent News

10/20/2026

Supernus Reaches Key Milestone Toward Proposed Merger with Indivior Following Shareholder Approval

Supernus Pharmaceuticals, Inc. welcomed the decisive backing of shareholders today, who formally voted to approve the pending all-stock merger of equals. This vote marks an important milestone toward completing the merger announced in August 2026, with closing anticipated on November 2, 2026, subject to customary closing conditions. Following closing, the combined organization will officially commence …

10/20/2026

GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026

GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are advancing scientific discovery, earlier diagnosis and more precise care. GeneDx research at ASHG 2026 highlights …

10/16/2026

Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”), which recently acquired Azora Therapeutics, today announced the appointment of David Rubenstein, M.D., Ph.D. as Chief Scientist. Dr. Rubenstein will lead the Company’s research and scientific strategy, including the continued development of AT177, a proprietary, oral, colon-targeted aryl hydrocarbon receptor (AhR) agonist being developed for the …